Idexx Laboratories (IDXX) Cost of Revenue (2009 - 2026)

Idexx Laboratories has reported Cost of Revenue for 18 years, with the latest figure at $437.5 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 5.49% year-over-year to $437.5 million in Q2 2026; TTM through Jun 2026 was $1.7 billion, a 10.11% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 8.27% from the prior year.
• Cost of Revenue was $437.5 million for Q2 2026 at Idexx Laboratories, up from $418.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $437.5 million in Q2 2026, with the low at $335.0 million in Q3 2022.
• Average Cost of Revenue over 5 years is $380.7 million, with a median of $375.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue retreated 0.73% in 2022, then advanced 12.73% in 2025.
• Over 5 years, Cost of Revenue stood at $343.6 million in 2022, then grew by 9.25% to $375.4 million in 2023, then gained by 2.18% to $383.6 million in 2024, then climbed by 12.73% to $432.5 million in 2025, then climbed by 1.16% to $437.5 million in 2026.
• The last three Cost of Revenue figures came in at $437.5 million (Q2 2026), $418.1 million (Q1 2026), and $432.5 million (Q4 2025), per Business Quant data.